CLSD

For the most part there is nothing to talk about until they meet with the FDA and finalize a trial design. And it's hard (but not impossible) to picture them advancing the product without a partner.

There are things to like about the approach and things not to like. FWIW the P1/2a extension data showed similar results to the P2b for duration, with the obvious caveat that the numbers are even smaller. They are using roughly twice as much drug as OCUL but in a smaller space (SC) in a suspension solution rather than sustained release. Axitinib works, the delivery results in durability and safety differences. How much you want to discount or promote one or the other is going to vary from one person to the next.

So I'm done talking on this ticker until they are in a position to start a P3 (one way or another).